News
Acrivon Therapeutics Presents Data At AACR Annual Meeting Highlighting Capabilities Of Acrivon Predictive Precision Proteomics For The Discovery Of ACR-2316, A Novel, Selective WEE1/PKMYT1 Inhibitor, And The Identification Of Actionable Resistance Mechanisms To ACR-368
10 Apr 24
Biotech, News, General
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
9 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 Apr 24
Movers
Dow Dips 150 Points; Laser Photonics Shares Spike Higher
9 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?
9 Apr 24
News, Financing, Movers
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings
9 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Global, Intraday Update, Markets, Trading Ideas
Market-Moving News for April 9th
9 Apr 24
Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
9 Apr 24
Movers
Ladenburg Thalmann Maintains Buy on Acrivon Therapeutics, Lowers Price Target to $14
5 Apr 24
News, Price Target, Analyst Ratings
BMO Capital Reiterates Outperform on Acrivon Therapeutics, Maintains $18 Price Target
1 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Acrivon Therapeutics: Q4 Earnings Insights
28 Mar 24
Earnings
Acrivon Therapeutics Q4 EPS $(0.86) Misses $(0.73) Estimate, Cash Balance of $127.5M
28 Mar 24
Earnings, News
12 Health Care Stocks Moving In Friday's Intraday Session
15 Mar 24
Movers
Acrivon Therapeutics To Present Data At AACR Annual Meeting Demonstrating Power Of Acrivon Predictive Precision Proteomics Platform And Its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
5 Mar 24
Biotech, News, General
JMP Securities Initiates Coverage On Acrivon Therapeutics with Market Outperform Rating, Announces Price Target of $14
1 Mar 24
News, Price Target, Initiation, Analyst Ratings
Press releases
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
16 Apr 24
News, Health Care, Press Releases
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
10 Apr 24
Health Care, Press Releases
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
8 Feb 24
News, Management, Press Releases